drugset
drugset / Trial / NCT01298830

GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

NCT01298830 ↗

Phase 1/2 Terminated 11 enrolled CellMed AG, a subsidiary of BTG plc.
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.

Timeline

Start
2008-10
Primary completion
2011-06
Completion
2011-06

Outcome

Outcome not reported

Stopped: “Need for improvement of study medication. Safety data collected sufficient. No further gain in knowledge expected.”

Drugs

EvaluationDrugModalityDoseRoute
Subject GLP-1 CellBeads Cell therapy 0.5 ml Other
Subject GLP-1 CellBeads Cell therapy 7.8e+06 cells Other

Indications

intracerebral hemorrhage